MedTrace Logo

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

NCT07146022 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 552

Last updated 2025-11-24

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA).

AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA.

This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).

Conditions

Interventions

DRUG

VDPHL01 QD

VDPHL01 Extended Release (ER) Tablet

DRUG

Placebo

Placebo tablet

DRUG

VDPHL01 BID

VDPHL01 Extended Release (ER) Tablet

DRUG

Placebo

Placebo tablet

Sponsors & Collaborators

  • Veradermics, Inc.

    lead INDUSTRY

Principal Investigators

  • Reid Waldman, M.D. · Veradermics, Inc.

  • Timothy Durso, M.D. · Veradermics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-25
Primary Completion
2027-06-30
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07146022 on ClinicalTrials.gov